Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein

Author:  ["Vladimir Y. Bogdanov","Viji Balasubramanian","James Hathcock","Oana Vele","Mark Lieb","Yale Nemerson"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Tissue factor (TF) is an essential enzyme activator that forms a catalytic complex with FVIIa and initiates coagulation by activating FIX and FX, ultimately resulting in thrombin formation1. TF is found in adventitia of blood vessels2 and the lipid core of atherosclerotic plaques3. In unstable coronary syndromes, plaque rupture initiates coagulation by exposing TF to blood4,5. Biologically active TF has been detected in vessel walls and circulating blood6. Elevated intravascular TF has been reported in diverse pro-thrombotic syndromes such as myocardial infarction, sepsis, anti-phospholipid syndrome and sickle-cell disease7,8,9,10. It is unclear how TF circulates, although it may be present in pro-coagulant microparticles11,12. We now report identification of a form of human TF generated by alternative splicing. Our studies indicate that alternatively spliced human tissue factor (asHTF) contains most of the extracellular domain of TF but lacks a transmembrane domain and terminates with a unique peptide sequence. asHTF is soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is incorporated into thrombi. We propose that binding of asHTF to the edge of thrombi contributes to thrombus growth by creating a surface that both initiates and propagates coagulation.

Cite this article

Bogdanov, V., Balasubramanian, V., Hathcock, J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9, 458–462 (2003). https://doi.org/10.1038/nm841

View full text

>> Full Text:   Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein

Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of P

A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by